Author: Michelow, Ian C.; Lear, Calli; Scully, Corinne; Prugar, Laura I.; Longley, Clifford B.; Yantosca, L. Michael; Ji, Xin; Karpel, Marshall; Brudner, Matthew; Takahashi, Kazue; Spear, Gregory T.; Ezekowitz, R. Alan B.; Schmidt, Emmett V.; Olinger, Gene G.
Title: High-Dose Mannose-Binding Lectin Therapy for Ebola Virus Infection Document date: 2011_1_15
ID: jvs25q21_3
Snippet: We previously reported preclinical studies that addressed the potential utility of recombinant human MBL (rhMBL) reconstitution therapy. MBL-knockout mice are highly susceptible to several bacteria including Staphylococcus aureus [1] . RhMBL improved survival in MBL-null mice to approximate survival among infected wild-type mice at doses that reconstituted the complement-activating capacity of MBL-knockout serum to a level comparable to that of w.....
Document: We previously reported preclinical studies that addressed the potential utility of recombinant human MBL (rhMBL) reconstitution therapy. MBL-knockout mice are highly susceptible to several bacteria including Staphylococcus aureus [1] . RhMBL improved survival in MBL-null mice to approximate survival among infected wild-type mice at doses that reconstituted the complement-activating capacity of MBL-knockout serum to a level comparable to that of wildtype mouse serum [1] . Doses of plasma-derived MBL and rhMBL designed to increase MBL concentrations to physiologic levels (.1000 ng/mL) in MBL-deficient humans were safe in early trials and did not elicit antibodies [3] [4] [5] . In contrast, although MBL replacement therapy enhanced opsonophagocytic potential, higher levels of plasma-derived MBL were needed to achieve MBL-mediated complement activation comparable to healthy controls [6] , suggesting that above-replacement dosing will need attention.
Search related documents:
Co phrase search for related documents- attention need and complement activation: 1
- attention need and high level: 1, 2, 3, 4, 5, 6, 7
- complement activate and healthy control: 1
- complement activate and MBL concentration: 1
- complement activation and healthy control: 1, 2, 3, 4, 5, 6
- complement activation and high level: 1, 2, 3, 4
- complement activation and MBL concentration: 1, 2, 3, 4, 5
- complement activation and MBL knockout: 1
- complement activation and MBL knockout serum: 1
- early trial and healthy control: 1
- healthy control and high level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- healthy control and MBL concentration: 1
- high level and MBL concentration: 1
Co phrase search for related documents, hyperlinks ordered by date